Table 2 Adjusted risk of thromboebolism
From: Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis
Variable | Hazard ratio for events (95% CI) | P value |
|---|---|---|
Age at diagnosis (years) | ||
≤70 | 1.00 | 0.221 |
>70 | 2.32 (0.60–8.98) | |
Tumor (T) size | ||
≤20 mm | 1.00 | 0.726 |
>20 mm | 0.68 (0.80–5.82) | |
Histological grade | ||
1, 2 | 1.00 | 0.650 |
3 | 1.28 (0.32–5.09) | |
Lymph node status | ||
Negativ | 1.00 | 0.650 |
Positiv | 0.70 (0.15–3.24) | |
HER2 status | ||
Negative | 1.00 | 0.782 |
Positive | 0.73 (0.08–6.59) | |
Blood vessel involvement | ||
Negative | 1.00 | 0.491 |
Positive | 2.20 (0.23–20.88) | |
Lymph vessel involvement | ||
Negative | 1.00 | 0.569 |
Positive | 1.54 (0.35–6.72) | |
Chemotherapy | ||
No | 1.00 | 0.375 |
Yes | 0.52 (0.12–2.23) | |
Radiation | ||
No | 1.00 | 0.258 |
Yes | 0.46 (0.12–1.77) | |
